Evidence map›Paper›PMID 40388084›Full record

ArticleEndocrine2025

CXCR4-directed PET with

Lu Tan, Tao Chen, Wenjie Zhang, Sikui Shen, Haoming Tian, Yuchun Zhu, Rong Tian, Yan Ren

Abstract read
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Real world experience with [Frontiers in endocrinology · 2026
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lu TanDepartment of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
Tao ChenDepartment of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
Wenjie ZhangDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
Sikui ShenDepartment of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
Haoming TianDepartment of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
Yuchun ZhuDepartment of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
Rong TianDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
Yan RenDepartment of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China. renyan@scu.edu.cn.

Funding

National Key Research and Development Program of China No.2021YFC2501601the Science and Technology Department of Sichuan Province project NO.23ZDYF2116
6 · The paper itself

Abstract

objectiveTo explore the accuracy of unilateral primary aldosteronism (UPA) classification via adrenal vein sampling (AVS) and C-X-C chemoking receptor 4 (CXCR4)-directed positron emission tomography (PET) with

methodsA retrospective cohort study was conducted with 89 patients who were diagnosed with UPA and who underwent unilateral adrenalectomy (ADX) at West China Hospital of Sichuan University from January 2021 to June 2023. For these patients, surgical decisions were made on the basis of either AVS (AVS group) or CXCR4-directed molecular imaging (CXCR4 group), and patients were regularly followed up for more than 6 months after surgery. Whether biochemical and clinical success was achieved 6 months after surgery was determined on the basis of the primary aldosteronism surgical outcomes (PASO) criterion. The complete success rates were compared between the AVS group and CXCR4 group. One-way analysis of variance was used to compare preoperative factors, postoperative biochemical success rates and clinical success rates between the two groups. Additionally, the postoperative outcomes of adrenal nodules of different sizes were compared.

results1. Among the 89 patients with UPA, 66 patients received ADX on the basis of AVS results, and 23 patients on the basis of CXCR4-directed molecular imaging results. The median age of the CXCR4 group [M (P25, P75): 45.00 years (39.00, 51.00)] was significantly lower than that of the AVS group [M (P25, P75): 49.00 years (40.75, 54.00)]. No significant differences in sex, history of hypertension, maximum blood pressure, antihypertensive drug defined daily dose (DDD), plasma aldosterone concentration (PAC), direct renin concentration (DRC), aldosterone-to-renin ratio (ARR), PAC after the captopril challenge test (CCT), PAC after the seated saline infusion test (SSIT), urea nitrogen, estimated glomerular filtration rate (eGFR), serum potassium level, diameter of the adrenal nodules or bilateral adrenal involvement were found. 2. There was no significant difference in the postoperative biochemical complete succcess rate (80.30 vs. 91.30%) or clinical cpmplete success rate (59.05 vs.65.21%) between the AVS group and the CXCR4 group. There were no significant differences in nitrogen, eGFR, serum potassium level, PAC, DRC, ARR, mean postoperative blood pressure or antihypertensive drug DDD after 6 months of follow-up. 3. For the identification of UPA patients with functional adrenal nodules ≥1 cm, CXCR4-directed molecular imaging have comparable diagnostic accuracies. 4. Three patients with adrenal micronodules achieved complete biochemical complete success after successful typing via CXCR4-directed molecular imaging, and unilateral aldosteronogenic micronodules were confirmed by immunohistochemistry (IHC) of CYP11B2 after surgery.

conclusionCXCR4-directed molecular imaging has high diagnostic value in diagnosing UPA. Patients with UPA diagnosed via CXCR4-directed molecular imaging achieved postoperative biochemical and clinical success, with outcomes that appear comparable to those of patients diagnosed on the basis of AVS. CXCR4-directed molecular imaging was more definitive for adrenal nodules larger than 1 cm.

Indexed as

Adrenal GlandsHyperaldosteronismPositron-Emission TomographyReceptors, CXCR4AdrenalectomyAdultCoordination ComplexesDrug CombinationsFemaleGallium RadioisotopesHumansMaleMiddle AgedPeptides, CyclicRetrospective StudiesVeins68Ga-pentixaforCoordination ComplexesCXCR4 protein, humanDrug CombinationsGallium RadioisotopesPeptides, CyclicReceptors, CXCR4Adrenal vein samplingCXCR4-directed molecular imagingCXCR4-directed PET with 68Ga-pentixaforPrimary aldosteronism surgical outcomes (PASO)Unilateral primary aldosteronism

Identifiers

PMID40388084
PMCPMC12289708

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.